Lenacapavir at $40 a Year Could Reshape HIV Prevention, Paired With a VR Molecular Viewer
US authorization of a generic lenacapavir priced at $40 per year for low- and middle-income countries could significantly expand HIV prevention worldwide. Lenacapavir is the first approved capsid inhibitor, a drug class that targets the viral protein shell rather than the enzymes targeted by conventional treatments. The drug binds between capsid subunits, stabilizing the structure and blocking viral uncoating, a mechanism that is hard to grasp from static 2D diagrams. NexoPeek, developed by Seven Sportz for Meta Quest, aims to make such molecular structures explorable in immersive virtual reality. The article describes the app's search tool, which pulls protein structure data from several public databases at once, and reports the author's test of viewing the HIV-1 capsid and the lenacapavir binding pocket.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)
Log in to join the discussion and vote.
Log in